Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo NanoTab Clear all
Completed Phase 2 Interventional Results available

A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain

NCT00833040
View directory record Official record
Conditions
Cancer, Pain
Interventions
Sublingual sufentanil NanoTabs™ and placebo NanoTabs™
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
13
States / cities
Montebello, California • Jacksonville, Florida • Lakeland, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2015 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure

NCT00894699
View directory record Official record
Conditions
Sedation, Anxiety, Pain
Interventions
Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03), Placebo NanoTab™
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery

NCT01660763
View directory record Official record
Conditions
Post Operative Pain
Interventions
Sufentanil NanoTab PCA System/15 mcg, Placebo Sufentanil NanoTab PCA System
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years and older
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Damascus, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy

NCT01710345
View directory record Official record
Conditions
Acute Pain
Interventions
Sufentanil NanoTab 20 mcg, Sufentanil NanoTab 30 mcg, Placebo NanoTab
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Pasadena, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery

NCT01539642
View directory record Official record
Conditions
Post-Operative Pain
Interventions
Sufentanil NanoTab PCA System/15 mcg, Placebo Sufentanil NanoTab PCA System
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Mobile, Alabama • Laguna Hills, California • Stamford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement

NCT00612534
View directory record Official record
Conditions
Post Operative Pain
Interventions
Sufentanil NanoTab, Placebo NanoTab
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
45 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2014 · Synced Oct 22, 2026, 2:38 PM EDT